The Food and Drug Administration (FDA) recommended lower dosage to check the cardiovascular events related to Erythropoiesis-Stimulating Agents (ESAs) which are used in anemia treatment for patients with chronic kidney diseases. Stroke, thrombosis and even death are the cardiovascular effects related to the dosing.